On this episode of Reaganism, Reagan Institute’s Director of the Center for Civics, Education, and Opportunity Dan Rothschild sits down with Dr. Ben Reinhardt who is the CEO of Speculative Technologies. They discuss discuss the mission and vision behind Speculative Technologies, emphasizing the importance of physical technologies and the need for innovative research funding models. Dr. Reinhardt critiques traditional government-funded research approaches and highlights the barriers to innovation in America, including bureaucratic constraints and the influence of venture capital. Reinhart advocates for a new system that allows for more flexibility and creativity in technology development, while also addressing the role of universities and the importance of co-location for fostering innovation.

On this episode of Reaganism, Reagan Institute Director Roger Zakheim sits down with retired General Jack Keane, who serves as the Chairman of the Institute for the Study of War. They discuss the ongoing military actions by Israel against Iran's nuclear weapons program, the implications for U.S. involvement, and the strategic landscape in the Middle East. He assesses the current state of the Iranian nuclear program, evaluates Israel's military options, and outlines the potential risks and benefits of U.S. engagement in the conflict. The discussion highlights the historical context of U.S.-Iran relations and the importance of supporting allies in the region.

On this episode of Reaganism, Reagan Institute Director Roger Zakheim sits down with Dr. Tevi Troy, a senior fellow at the Reagan Institute and former deputy secretary of Health and Human Services. They discuss Dr. Troy's article 'In Praise of Big Pharma,' exploring the critical role of the pharmaceutical industry in healthcare innovation and the challenges it faces from government regulation and public perception. The conversation also touches on the importance of vaccines, the impact of government policies on healthcare costs, and the future of American innovation in the pharmaceutical sector, particularly in the context of competition with China.